NASDAQ$DSGN
Design Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · After market close · Investor relations
Briefing
Design Therapeutics Inc reported its Q2 2024 financial results with a net loss of $11.8 million.
The company continued advancing its GeneTAC platform with focus on DT-216P2 for Friedreich ataxia and DT-168 for FECD. Operating expenses decreased year-over-year due to completion of prior clinical activities. Cash position remained strong at $261 million supporting ongoing development.
- Q2 2024 net loss of $11.8 million, improved from $19.9 million in Q2 2023
- R&D expenses reduced to $10.5 million from $17.1 million year-over-year
- Cash and securities totaled $261 million at quarter end
- Plans to submit new IND for DT-216P2 and initiate Phase 1 trials in 2025
Headline financials
Revenue & EPS history
Design Therapeutics · Revenue · Quarterly
$0
Forward guidance
Company plans to complete GLP studies for DT-216P2 by end of 2024 and initiate clinical trials in 2025 subject to regulatory clearance.
Tailwinds
- Strong cash position of $261 million
- Reduced operating expenses
- Progress on formulation improvements for DT-216P2
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-2.2%
Avg return
Earnings day
+1.7%
Avg return
5 days after
+3.2%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+15.1%
Q4 2023
Best reaction
-71.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q1 2026 | +0.0% | +3.8% | -16.2% | |
| Q4 2025 | +3.2% | +0.7% | +26.1% | |
| Q3 2025 | +10.7% | +10.8% | +42.2% | |
| Q2 2025 | -8.9% | +14.5% | +48.3% | |
| Q1 2025 | +0.3% | +10.3% | +10.3% | |
| Q4 2024 | +0.4% | +2.5% | -27.2% | |
| Q3 2024 | -1.9% | +16.3% | +7.9% | |
| Q1 2024 | +1.7% | -3.0% | -17.9% | |
| Q4 2023 | +15.1% | +50.8% | +48.4% | |
| Q3 2023 | +13.9% | +10.4% | +27.4% | |
| Q2 2023 | -71.7% | -72.8% | -65.2% | |
| Q1 2023 | -12.2% | -12.6% | -26.4% | |
| Q4 2022 | -0.6% | -8.1% | -24.8% | |
| Q3 2022 | -0.3% | -0.8% | -9.7% | |
| Q2 2022 | +0.3% | +13.5% | +5.5% | |
| Q1 2022 | -1.5% | -2.4% | +30.9% | |
| Q4 2021 | -1.8% | -0.8% | -10.0% | |
| Q3 2021 | +4.8% | +10.7% | -3.8% | |
| Q2 2021 | +9.9% | +7.9% | +19.7% | |
| Q1 2021 | -6.0% | -18.0% | -1.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro